Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy

Epilepsia
T KondoI Egawa

Abstract

We wished to assess the risk of teratogenicity of zonisamide (ZNS) in humans. Pregnant epileptic women treated with ZNS and their offspring were prospectively monitored from June 1989 to December 1994. The outcome of pregnancy and status of neonates were examined based on the same standardized protocol. Twenty-six offspring exposed to ZNS with or without other antiepileptic drugs (AEDs) were studied. Malformations were detected in 2 offspring (7.7%) exposed to ZNS polypharmacy. Anencephaly was detected in one case at 16 weeks of gestation (case 1, artificial abortion), and atrial septal defect was detected in another case at 37 weeks of gestation (case 2, delivery by cesarean section). Serum concentrations of ZNS during the first trimester of pregnancy were 6.1 micrograms/ml in case 1 and 6.3 micrograms/ml in case 2; in both cases, the levels were below the therapeutic concentration range of ZNS. Teratogenic effects of ZNS were not clearly defined from these results since malformations were detected in two polypharmacy cases but not in four monopharmacy cases. The present data do not indicate that the risk of ZNS teratogenicity is greater than that of other conventional AEDs. However, such risk cannot be neglected even at thera...Continue Reading

Citations

May 10, 2012·Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery·Füsun Demirçivi OzerMeral Baka
Feb 28, 2007·Current Neurology and Neuroscience Reports·Tarannum Musvee Lateef, Karin B Nelson
Apr 16, 2011·Current Treatment Options in Neurology·Laura Mantoan, Matthew Walker
Jul 27, 2001·Neurologic Clinics·S C Schachater
May 29, 2003·Pediatric Neurology·James F KnudsenJudith A Racoosin
Apr 21, 1999·Epilepsy Research·M OkadaS Kaneko
Aug 26, 2006·Nature Clinical Practice. Neurology·Alison M Pack
Oct 26, 1999·Epilepsia·I E Leppik
Jan 13, 2001·Epilepsia·S Kaneko
Jul 10, 2002·Clinical Pharmacokinetics·James W McAuley, Gail D Anderson
Jan 24, 2014·BioMed Research International·Kamal M Matar
Mar 14, 2002·Brain & Development·Kou KawadaMami Ishii
Dec 1, 2006·European Journal of Pediatrics·Nobuko KanemotoTadao Arinami
Apr 29, 1998·Current Opinion in Neurology·J W Sander
Jul 13, 2006·Expert Review of Neurotherapeutics·William O Tatum
Jun 4, 2010·Expert Review of Neurotherapeutics·Denise S HillRichard H Finnell
Jun 15, 2011·Expert Opinion on Drug Safety·Gaetano ZaccaraMassimo Cincotta
Sep 4, 2015·Expert Opinion on Drug Safety·Alberto VerrottiGaetano Zaccara
Apr 25, 2008·Expert Opinion on Drug Metabolism & Toxicology·Sanjeev V Kothare, Joseph Kaleyias
Aug 23, 2005·Expert Opinion on Drug Safety·Stephen J Hunt, Jim I Morrow
Mar 8, 2008·Expert Opinion on Drug Safety·Mervyn J Eadie
Jul 17, 2008·Expert Opinion on Pharmacotherapy·F J E Vajda
Jul 29, 2000·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·I C Wong, S D Lhatoo
Mar 9, 2010·Thérapie·Marie-Clémence VerdierUNKNOWN le groupe Suivi Thérapeutique Pharmacologique de la Société Française de Pharmacologie et de Thérapeutique
Oct 27, 2009·Neurologic Clinics·Torbjörn Tomson, Dina Battino
Jul 31, 2007·Epilepsy & Behavior : E&B·Joyce A CramerOrrin Devinsky
Mar 6, 2003·Neurologic Clinics·Ann M Bergin, Mary Connolly
Oct 30, 2004·Seizure : the Journal of the British Epilepsy Association·Shunsuke Ohtahara, Yasuko Yamatogi
Feb 19, 2014·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Frank J E Vajda
Feb 3, 2007·Seizure : the Journal of the British Epilepsy Association·Shunsuke Ohtahara, Yasuko Yamatogi
Jul 19, 2012·Lancet Neurology·Torbjörn Tomson, Dina Battino
Oct 3, 2006·Expert Review of Neurotherapeutics·Alexis Arzimanoglou, Abdallah Rahbani
Jun 26, 2008·The Annals of Pharmacotherapy·Karen S Oles, William L Bell
Jan 31, 2002·The Annals of Pharmacotherapy·James W McAuleyJ Layne Moore
Dec 17, 2009·Expert Opinion on Pharmacotherapy·Andreas Schulze-Bonhage
Dec 1, 1998·CNS Drug Reviews·Yoshinobu MasudaMasanao Shimizu
Jun 2, 2012·Expert Review of Neurotherapeutics·Arne Reimers, Eylert Brodtkorb

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.